CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase 1. In Phase 2, assessment of ziftomenib wil...
Phase 1, Phase 2
Los Angeles, California, United States and 51 other locations
in children and adolescents with newly diagnosed chronic myeloid leukemia (CML), or in children with Ph+ acute lymphoblastic leukemia...
Phase 2
Long Beach, California, United States and 173 other locations
Phase 2 dose (RP2D) of SNDX-5613 in participants with acute leukemia.In Phase 2, participants will be enrolled in 3 indication-specific expa...
Phase 1, Phase 2
Los Angeles, California, United States and 47 other locations
(bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL). Participants will be enrolled into 3 following cohorts: tre...
Phase 3
Whittier, California, United States and 105 other locations
An open label, ascending dose study for adult subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)...
Phase 1, Phase 2
Los Angeles, California, United States and 8 other locations
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia....
Phase 1
Los Angeles, California, United States and 23 other locations
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of JNJ-75276617 in Part 1 (Dose Escalation) and to determine safe...
Phase 1, Phase 2
Duarte, California, United States and 23 other locations
This study is a Phase 1, open-label, dose escalation, and cohort expansion study designed to characterize the safety, tolerability, pharmacokinetics,...
Phase 1
Duarte, California, United States and 8 other locations
with relapsed or refractory B-cell acute lymphoblastic leukemia with high bone marrow lymphoblast percentage (>50% lymphoblasts)....
Phase 1, Phase 2
Orange, California, United States and 3 other locations
complete outpatient blinatumomab administration for subjects with minimal/measurable residual disease (MRD) of B-precursor Acute Lymphoblastic Leukemia...
Phase 4
Los Angeles, California, United States and 11 other locations
Clinical trials
Research sites
Resources
Legal